Study of Biocompatibility and Antibacterial Properties of Titanium Substrates Coated With Chitosan Reinforced With Graphene Oxide

Gheysoor, Mahsa; Faghihi, Shahab

doi:10.30699/ijmm.12.107

year 12, Issue 2 (May - June 2018) Iran J Med Microbiol 2018, 12(2): 107-115 | Back to browse issues page

‎ 10.30699/ijmm.12.107

Mendeley

Zotero

RefWorks

Gheysoor M, Faghihi S. Study of Biocompatibility and Antibacterial Properties of Titanium Substrates Coated With Chitosan Reinforced With Graphene Oxide. Iran J Med Microbiol 2018; 12 (2) :107-115
URL: http://ijmm.ir/article-1-812-en.html

Study of Biocompatibility and Antibacterial Properties of Titanium Substrates Coated With Chitosan Reinforced With Graphene Oxide

Mahsa Gheysoor¹

, Shahab Faghihi²

1- Department of Stem Cells and Regenerative Medicine, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
2- Department of Stem Cells and Regenerative Medicine, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran , shahabeddin.faghihi@mail.mcgill.ca

Abstract: (6368 Views)

Background and Aims: In this study graphene oxide based coatings are applied on the titanium substrates in order to improve their biocompatibility and antibacterial properties of titanium substrate.
Materials and Methods: Chitosan, graphene oxide and their composites separately are coated on the substrates and their hydrophilicity and roughness are measured using contact angle measurement and atomic force microscopy. The coated substrates are then exposed to MG63 osteoblasts and Staphylococcus aureus in order to evaluate the interactions.
Results: The results show that titanium samples that are coated with chitosan and composites have better surface hydrophilicity and higher roughness compared to other samples and uncoated titanium. Cell adhesion is also improved on the coated substrates. Regarding the antibacterial property the composite coating show the best results.
Conclusions: It is concluded that the titanium substrate which is coated with nanocomposite of graphene oxide and chitosan has higher hydrophilicity and roughness that resulted to enhance biocompatibility and antibacterial property. This may lead to a higher success rate in the application of these substrates in maxillofacial implant surgeries.

Keywords: Titanium, Graphene Oxide, Chitosan, Biocompatibility, Antibacterial

Full-Text [PDF 959 kb] (3180 Downloads)

Type of Study: Original Research Article | Subject: Nanotechnology In Medicine
Received: 2018/02/3 | Accepted: 2018/06/25 | ePublished: 2018/07/15

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424. [DOI:10.3322/caac.21492] [PMID]

2. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, et al. Bladder cancer. Lancet. 2016;388(10061):2796-810. [DOI:10.1016/S0140-6736(16)30512-8] [PMID]

3. Richterstetter M, Wullich B, Amann K, Haeberle L, Engehausen DG, Goebell PJ, et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU international. 2012;110(2b):E76-E9. [DOI:10.1111/j.1464-410X.2011.10904.x] [PMID]

4. Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol. 2013;23(5):435-43. [DOI:10.1097/MOU.0b013e328363e415] [PMID]

5. Lopez Beltran A, Montironi R, Cheng L. Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. Histopathology. 2014;64(6):872-9. [DOI:10.1111/his.12345] [PMID]

6. Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. bmj. 2018;362. [DOI:10.1136/bmj.k3519] [PMID] [PMCID]

7. Bayat A-A, Sadeghi N, Fazli G, Nowroozi MR, Moghadam SO, Radmanesh A, et al. Diagnostic and Therapeutic Implications of Sortilin Expressed on the Surface of Bladder Carcinoma Cells. Iran J Pathol. 2022;17(2):174. [DOI:10.30699/ijp.2022.539411.2732] [PMID] [PMCID]

8. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. European urology. 2016;70(1):93-105. [DOI:10.1016/j.eururo.2016.02.029] [PMID]

9. Amin MB, Trpkov K, Lopez-Beltran A, Grignon D, Group IIiDUP. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e20-e34. [DOI:10.1097/PAS.0000000000000240] [PMID]

10. Walter B, Weiss T, Hofstädter F, Gaumann A, Hartmann A, Rogenhofer S, et al. Utility of immunohistochemistry markers in the interpretation of post-high-intensive focussed ultrasound prostate biopsy cores. World J Urol. 2013;31:1129-33. [DOI:10.1007/s00345-012-0838-9] [PMID]

11. Rezakhaniha B, Pour NA, Siroosbakhat S. Effect of cystoscopy on prostate-specific antigen, new words about old subject. Int J Cancer Manag. 2010;3(4).

12. Sirousbakht S, Rezakhaniha B. Effect of colonoscopy on prostate-specific antigen; new words about an old subject. Int J Cancer Manag. 2018;11(7). [DOI:10.5812/ijcm.68919]

13. Boron M, Hauzer-Martin T, Keil J, Sun X-L. Circulating thrombomodulin: release mechanisms, measurements, and levels in diseases and medical procedures. TH Open. 2022;6(03):e194-e212. [DOI:10.1055/a-1801-2055] [PMID] [PMCID]

14. Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care. 2019;23:1-11. [DOI:10.1186/s13054-019-2552-0] [PMID] [PMCID]

15. Giri H, Panicker SR, Cai X, Biswas I, Weiler H, Rezaie AR. Thrombomodulin is essential for maintaining quiescence in vascular endothelial cells. Proc Natl Acad Sci U S A. 2021;118(11):e2022248118. [DOI:10.1073/pnas.2022248118] [PMID] [PMCID]

16. Wu C-T, Chang Y-H, Lin P-Y, Chen W-C, Chen M-F. Thrombomodulin expression regulates tumorigenesis in bladder cancer. BMC Cancer. 2014;14:1-11. [DOI:10.1186/1471-2407-14-375] [PMID] [PMCID]

17. Yang Y, Cheng B-J, Lu S. Thrombomodulin regulates doxorubicin sensitivity through epithelial-mesenchymal transition in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017;21(1).

18. Kondo T, Takahashi M, Yamasaki G, Sugimoto M, Kuse A, Morichika M, et al. Immunohistochemical analysis of thrombomodulin expression in myocardial tissue from autopsy cases of ischemic heart disease. Legal Medicine. 2021;51:101897. [DOI:10.1016/j.legalmed.2021.101897] [PMID]

19. Cheng T-L, Lai C-H, Chen P-K, Cho C-F, Hsu Y-Y, Wang K-C, et al. Thrombomodulin promotes diabetic wound healing by regulating toll-like receptor 4 expression. J Invest Dermatol. 2015;135(6):1668-75. [DOI:10.1038/jid.2015.32] [PMID]

20. Aboalkher MM, Elsayed SK, Sayed SS, Galal SA. Thrombomodulin in skin diseases. J Recent Adv Med. 2021;2(2):230-5. [DOI:10.21608/jram.2021.53156.1104]

21. Han C, Dong J-f. Saving placental thrombomodulin. Blood. 2021;137(7):873-4. [DOI:10.1182/blood.2020008659] [PMID] [PMCID]

22. Nozaki Y, Ri J, Sakai K, Niki K, Funauchi M, Matsumura I. Protective effects of recombinant human soluble thrombomodulin on lipopolysaccharide-induced acute kidney injury. International Journal of Molecular Sciences. 2020;21(7):2519. [DOI:10.3390/ijms21072519] [PMID] [PMCID]

23. van Aanhold CC, Dijkstra KL, Bos M, Wolterbeek R, van den Berg BM, Bruijn JA, et al. Reduced glomerular endothelial thrombomodulin is associated with glomerular macrophage infiltration in diabetic nephropathy. Am J Pathol. 2021;191(5):829-37. [DOI:10.1016/j.ajpath.2021.02.002] [PMID]

24. Watanabe-Kusunoki K, Nakazawa D, Ishizu A, Atsumi T. Thrombomodulin as a physiological modulator of intravascular injury. Front Immunol. 2020;11:575890. [DOI:10.3389/fimmu.2020.575890] [PMID] [PMCID]

25. Abogunrin F, O'Kane HF, Ruddock MW, Stevenson M, Reid CN, O'Sullivan JM, et al. The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer. 2012;118(10):2641-50. [DOI:10.1002/cncr.26544] [PMID]

26. Ye F, Wang L, Castillo-Martin M, McBride R, Galsky MD, Zhu J, et al. Biomarkers for bladder cancer management: present and future. American journal of clinical and experimental urology. 2014;2(1):1. [PMID]

27. Sb E, Dr B, CC C, AG F, FL G. AJCC cancer staging manual. New York: Springer. 2010;6(9):347-76.

28. Martin FA, McLoughlin A, Rochfort KD, Davenport C, Murphy RP, Cummins PM. Regulation of thrombomodulin expression and release in human aortic endothelial cells by cyclic strain. PLoS One. 2014;9(9):e108254. [DOI:10.1371/journal.pone.0108254] [PMID] [PMCID]

29. Ella-Tongwiis P, Lamb RM, Makanga A, Shergill I, Hughes SF. The role of antibody expression and their association with bladder cancer recurrence: A single-centre prospective clinical-pilot study in 35 patients. BMC urology. 2020;20:1-11. [DOI:10.1186/s12894-020-00759-3] [PMID] [PMCID]

30. Watt J, Maguire DG, Reid CN, Lamont JV, Fitzgerald SP, Ruddock MW. Thrombomodulin expression in bladder cancer tissue and its association with prognosis and patient survival. Research and Reports in Urology. 2020:157-65. [DOI:10.2147/RRU.S249417] [PMID] [PMCID]

31. Kalan Farmanfarma K, Mahdavifar N, Salehiniya H. Bladder cancer in Iran: an epidemiological review. Research and Reports in Urology. 2020:91-103. [DOI:10.2147/RRU.S232417] [PMID] [PMCID]

32. Chang Y-J, Cheng Y-W, Lin R-K, Huang C-C, Chen WT-L, Ke T-W, et al. Thrombomodulin influences the survival of patients with non-metastatic colorectal cancer through epithelial-to-mesenchymal transition (EMT). PLoS One. 2016;11(8):e0160550. [DOI:10.1371/journal.pone.0160550] [PMID] [PMCID]

33. Parker DC, Folpe AL, Bell J, Oliva E, Young RH, Cohen C, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. The American journal of surgical pathology. 2003;27(1):1-10. [DOI:10.1097/00000478-200301000-00001] [PMID]

34. Mhawech P, Uchida T, Pelte M-F. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33(11):1136-40. [DOI:10.1053/hupa.2002.129416] [PMID]

35. Refaat LA, Ali OE, Hassan AA, Metwally AM. Urinary thrombomodulin is down regulated in schistosomiasis associated bladder cancer. J Genet Eng Biotechnol. 2012;10(1):67-71. [DOI:10.1016/j.jgeb.2012.04.003]

36. Hanly A, Redmond M, Winter D, Brophy S, Deasy J, Bouchier-Hayes D, et al. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer. 2006;94(9):1320-5. [DOI:10.1038/sj.bjc.6603098] [PMID] [PMCID]

37. Karimaei S, Mashhadi R, Mirzaei A, Deyhimfar R, Shabestari AN, Rahimnia R. Antibacterial and antibiofilm activities of nisin from Lactococcus lactis and alteration of the bacteria-induced pro-inflammatory responses on kidney and bladder tumor cell lines. Transl Res Urol 2022;4(1):47-53. [DOI:10.22034/tru.2022.334240.1106]

38. Tai C-J, Cheng C-W, Su H-Y, Chen W-Y, Wu C-T, Lin F-Y, et al. Thrombomodulin mediates the migration of cervical cancer cells through the regulation of epithelial-mesenchymal transition biomarkers. Tumour Biol. 2014;35:47-54. [DOI:10.1007/s13277-013-1005-7] [PMID]

39. Fallah B, Barikzaei P, Barikzehi M, Khalili N, Nasiriani K, BagherAbadi M. Effect of telenursing on life quality and care burden of caregivers in patients undergoing bladder tumor resection through duct. Transl Res Urol. 2022;4(3):145-50. [DOI:10.22034/tru.2022.352557.1117]